Unfortunately, our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D,… — Kiran Mazumdar-Shaw Copy Share Image
In Vedic times, we had the great quest for the unknown. We did wonderful things; we celebrate our past vigyaan and our wonderful heritage… — Kiran Mazumdar-Shaw Copy Share Image
People believe that art and science are two distinct realms. It is far from the truth because, if you look at science from a… — Kiran Mazumdar-Shaw Copy Share Image
Unfortunately, our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon… — Kiran Mazumdar-Shaw Copy Share Image
I want to make sure that our bio-similars capture a huge market share and help cancer patients around the world, which we are already… — Kiran Mazumdar-Shaw Copy Share Image
I have successfully challenged the Western world's existing model of pharmaceutical innovation, which leads to the creation of monopolistic markets for novel, life-saving drugs… — Kiran Mazumdar-Shaw Copy Share Image
I faced a number of challenges whilst I built Biocon. Initially, I had credibility challenges where I couldn't get banks to fund me; I… — Kiran Mazumdar-Shaw Copy Share Image
We need to ask ourselves: What use is our scientific endeavor and innovation when they are inaccessible to the people who need them the… — Kiran Mazumdar-Shaw Copy Share Image
As a traditionally risk-averse nation, India has rarely been at the forefront of innovation. Indian companies have mostly imitated others and became very good… — Kiran Mazumdar-Shaw Copy Share Image
Innovation and commerce are as powerful tools for creating social progress as they are for driving technological advancement. — Kiran Mazumdar-Shaw Copy Share Image
